SCHEMBL7713772

SCHEMBL7713772

COc1c(OC(F)F)ccc(-c2cccc3c2CCC3=O)c1OCC1(C)COC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40
S1PR1 P21453 1/20 0.33
PDE4D Q08499 1/20 0.32
DHFR P00374 1/20 0.31
DCPS Q96C86 1/20 0.31
TUBB4A P04350 1/20 0.31
TUBB P07437 1/20 0.31
TUBA3C P0DPH7 1/20 0.31
TUBA1B P68363 1/20 0.31
TUBA4A P68366 1/20 0.31
TUBB4B P68371 1/20 0.31
TUBB3 Q13509 1/20 0.31
TUBB2A Q13885 1/20 0.31
TUBB8 Q3ZCM7 1/20 0.31
TUBA3E Q6PEY2 1/20 0.31
TUBA1A Q71U36 1/20 0.31
TUBA1C Q9BQE3 1/20 0.31
TUBB6 Q9BUF5 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2591412 0.90 ALDH1A1 (0.51) KDM4EALDH1A1HPGDS1PR1PDE4D
SCHEMBL14736925 0.90 KDM4E (0.40) KDM4EALDH1A1HPGDS1PR1PDE4D
SCHEMBL14736831 0.89 KDM4E (0.39) KDM4EALDH1A1HPGDS1PR1PDE4D
SCHEMBL7715294 0.87 ALDH1A1 (0.43) KDM4EALDH1A1HPGDS1PR1PDE4D
SCHEMBL7714064 0.86 KDM4E (0.51) KDM4EALDH1A1HPGDS1PR1PDE4D
SCHEMBL2588337 0.84 ALDH1A1 (0.47) KDM4EALDH1A1HPGDS1PR1PDE4D
SCHEMBL2593781 0.83 ALDH1A1 (0.46) KDM4EALDH1A1HPGDS1PR1PDE4D
SCHEMBL14737319 0.82 KDM4E (0.42) KDM4EALDH1A1HPGDS1PR1PDE4D
SCHEMBL2585947 0.82 ALDH1A1 (0.45) KDM4EALDH1A1HPGDS1PR1PDE4D
SCHEMBL2589070 0.82 ALDH1A1 (0.45) KDM4EALDH1A1HPGDS1PR1PDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2563770-B1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA AS (DK) 2016-03-23 EP disclosed
US-9051290-B2 Biaryl phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-06-09 US disclosed
US-9051290-B2 Biaryl phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-06-09 US disclosed
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-03-07 US disclosed
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-03-07 US disclosed
WO-2011134468-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2011-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS PDE3B, PDE3A, PDE4A KDM4E 1593/4885ALDH1A1 824/4885HPGD 1088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.